Which mutations benefit most from PARP inhibitors in prostate cancer?

Which mutations benefit most from PARP inhibitors in prostate cancer?

BRCA & PARP Inhibitors: Targeted Chemotherapy | #MarkScholzMD #AlexScholz @PCRIПодробнее

BRCA & PARP Inhibitors: Targeted Chemotherapy | #MarkScholzMD #AlexScholz @PCRI

UROwebinar: Parp inhibitors in Prostate Cancer - Part 1Подробнее

UROwebinar: Parp inhibitors in Prostate Cancer - Part 1

Modern Treatment Approaches to Prostate CancerПодробнее

Modern Treatment Approaches to Prostate Cancer

11.23.2020 Urology COViD Didactics - Management of Advanced Prostate CancerПодробнее

11.23.2020 Urology COViD Didactics - Management of Advanced Prostate Cancer

ACTG Dinner Symposium Highlights | Beyond BRCA testing – does HRD matter? | Prof Michael FriedlanderПодробнее

ACTG Dinner Symposium Highlights | Beyond BRCA testing – does HRD matter? | Prof Michael Friedlander

Screening for Prostate CancerПодробнее

Screening for Prostate Cancer

Boxer Lecture 2015, Lewis C. Cantley, PhD - PI 3-Kinase and Cancer MetabolismПодробнее

Boxer Lecture 2015, Lewis C. Cantley, PhD - PI 3-Kinase and Cancer Metabolism

События